What it is: A synthetic analog of IGF-1 with structural modifications that extend its half-life to approximately 20-30 hours and dramatically increase its biological potency.
Research suggests: Strongly promotes muscle protein synthesis and cellular repair; most direct human evidence is extrapolated from clinical trials of native recombinant IGF-1.
Best for: Anabolic and body composition researchers
Key thing to know: Hypoglycemia risk is well-documented and significant; blood glucose monitoring is a standard consideration in any research protocol involving this compound.
What is IGF-1 LR3?
IGF-1 LR3 (Insulin-like Growth Factor 1 Long R3) is a synthetic analog of naturally occurring IGF-1, engineered with two structural modifications: an arginine substitution at position 3 and an additional 13-amino-acid extension at the N-terminus. These modifications reduce its binding affinity to IGF binding proteins (IGFBPs) - proteins that normally sequester IGF-1 in circulation and limit its bioactivity. The result is a compound with significantly greater potency and a half-life approximately 120 times longer than endogenous IGF-1.
Endogenous IGF-1 is produced primarily in the liver in response to growth hormone (GH) signaling and plays a central role in the GH/IGF-1 axis - one of the body's primary anabolic signaling systems. It promotes cellular growth, protein synthesis, glucose uptake, and muscle repair. IGF-1 LR3 was developed as a research tool to study the effects of sustained IGF-1 receptor activation without the short half-life limitations of native IGF-1.
Research interest is concentrated in areas of skeletal muscle hypertrophy, recovery from injury, fat metabolism, and the cellular biology of aging. It is not FDA approved for human use and carries a distinct risk profile due to its potency and mitogenic properties.
How it works.
IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor expressed on nearly all cell types. This binding triggers autophosphorylation of the receptor and downstream activation of two primary signaling cascades: the PI3K/Akt/mTOR pathway (which drives protein synthesis, cell growth, and survival) and the MAPK/ERK pathway (which promotes cell proliferation and differentiation).
The mTOR pathway is particularly relevant to skeletal muscle. Activation of mTORC1 increases ribosomal biogenesis and protein translation, leading to measurable increases in muscle protein synthesis rates. Research in cell culture and preclinical studies shows that IGF-1 LR3 can initiate satellite cell activation - the proliferation of muscle stem cells that repair and add to existing muscle fibers following mechanical stress or injury.
Because IGF-1 LR3 has reduced IGFBP binding, a higher fraction of the administered compound remains free and biologically active compared to native IGF-1. Its extended half-life (approximately 20–30 hours versus 12–15 minutes for endogenous IGF-1) means it produces prolonged receptor activation - a meaningful difference for research on sustained anabolic signaling, but also a source of concern regarding unchecked mitogenic activity in tissues with pre-existing cellular abnormalities.
What the research shows.
The evidence base for IGF-1 LR3 is split between robust in vitro and animal research on one side, and limited direct human data on the other. In cell culture and rodent studies, IGF-1 LR3 consistently demonstrates enhanced muscle protein synthesis, accelerated satellite cell proliferation, improved glycogen storage, and reduced adipogenesis. These mechanistic effects are well-characterized and replicated across independent research groups.
Human data is more limited. Much of the evidence applied to IGF-1 LR3 is extrapolated from clinical trials on native recombinant IGF-1 (mecasermin), which has been studied in conditions including growth hormone insensitivity syndrome and ALS. These studies demonstrate that IGF-1 receptor activation in humans produces measurable anabolic effects and influences insulin sensitivity, providing mechanistic plausibility for LR3's effects - but the specific pharmacokinetics and safety profile of the LR3 analog in humans have not been directly studied in controlled trials.
The research chemical context adds complexity: IGF-1 LR3 is used in research settings but has not undergone the clinical trial pipeline required to characterize its human safety profile at various doses and durations. The absence of clinical data is not evidence of ineffectiveness, but it does mean the risk profile in humans is not well-established.
Biomarkers to review first.
Research protocols for IGF-1 LR3 typically reference the following biomarkers as critical baseline context. Given IGF-1 LR3's effects on insulin signaling and cellular growth, these markers are especially important to understand before any protocol consideration.
What it's commonly researched with.
In research literature, IGF-1 LR3 is frequently examined in combination with growth hormone secretagogues and recovery-focused peptides. The combinations below represent what researchers have studied - not recommendations for use.